Back to top
more

Champions Oncology (CSBR)

(Delayed Data from NSDQ)

$5.03 USD

5.03
4,183

-0.20 (-3.73%)

Updated Apr 17, 2024 03:03 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (145 out of 251)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Champions Oncology, Inc. (CSBR) Reports Q3 Loss, Tops Revenue Estimates

Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -200% and 2.26%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings and Revenue Estimates

Amneal (AMRX) delivered earnings and revenue surprises of 9.52% and 4.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of 20.69% and 132.98%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Champions Oncology (CSBR) Stock Options

Investors need to pay close attention to Champions Oncology (CSBR) stock based on the movements in the options market lately.

Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 7.30% and 9.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) Reports Q3 Loss, Tops Revenue Estimates

MediWound (MDWD) delivered earnings and revenue surprises of -30% and 24.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Infinity Pharmaceuticals (INFI) Reports Q3 Loss, Lags Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of -140% and 91.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Champions Oncology, Inc. (CSBR) Reports Q1 Loss, Tops Revenue Estimates

Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -300% and 2.27%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?

Has Champions Oncology, Inc. (CSBR) Outpaced Other Medical Stocks This Year?

Here is how Champions Oncology, Inc. (CSBR) and Gamida Cell (GMDA) have performed compared to their sector so far this year.

Jounce Therapeutics, Inc. (JNCE) Reports Q4 Loss, Lags Revenue Estimates

Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of -156.52% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Champions Oncology, Inc. (CSBR) Reports Q1 Loss, Tops Revenue Estimates

Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -200.00% and 2.30%, respectively, for the quarter ended July 2021. Do the numbers hold clues to what lies ahead for the stock?

Champions Oncology, Inc. (CSBR) Reports Next Week: What You Should Expect

Champions Oncology, Inc. (CSBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Champions Oncology, Inc. (CSBR) Upgraded to Buy: What Does It Mean for the Stock?

Champions Oncology, Inc. (CSBR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Strength Seen in Champions Oncology, Inc. (CSBR): Can Its 15.3% Jump Turn into More Strength?

Champions Oncology, Inc. (CSBR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Analysts Estimate Champions Oncology, Inc. (CSBR) to Report a Decline in Earnings: What to Look Out for

Champions Oncology, Inc. (CSBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for January 11th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Champions Oncology (CSBR) Catches Eye: Stock Jumps 9.2%

Champions Oncology (CSBR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

The Keys to Successfully Timing the Markets - August 18, 2020

Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?

When Does Market Timing Actually Work? - July 29, 2020

Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?

Timing the Market, Is it Possible? - July 07, 2020

Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?

Timing the Market, Is it Possible? - April 28, 2020

Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?

Yes, You Can Time the Market. Find out How - April 02, 2020

Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?